A COVID-19 vaccine candidate was found to be safe and well-tolerated, though the study was small (45 patients).
8 patients were examined for antibodies and it was found, in all 8, that the vaccine prompted the production of neutralizing antibodies at or above the level produced in the same time frame by normal infection by the disease.
The goal of phase 1 trials is to evaluate the safety of a new drug at selected doses in a small group of healthy volunteer participants. It is therefore not focused on effectiveness.
Phase 2 trials study whether a drug works. That comes next, then phase 3, then review, then approval.
Good news, for a new technology. RNA vaccines should be easier to be mass-produced, though none have yet made it to market.
link: https://www.nbcnews.com/health/heal...qckjYYohRzKe7D7BZMpEdpEuXH7GPD_T-pLJ8jLOavF6I
8 patients were examined for antibodies and it was found, in all 8, that the vaccine prompted the production of neutralizing antibodies at or above the level produced in the same time frame by normal infection by the disease.
The goal of phase 1 trials is to evaluate the safety of a new drug at selected doses in a small group of healthy volunteer participants. It is therefore not focused on effectiveness.
Phase 2 trials study whether a drug works. That comes next, then phase 3, then review, then approval.
Good news, for a new technology. RNA vaccines should be easier to be mass-produced, though none have yet made it to market.
link: https://www.nbcnews.com/health/heal...qckjYYohRzKe7D7BZMpEdpEuXH7GPD_T-pLJ8jLOavF6I